STOCK TITAN

[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Galectin Therapeutics (GALT) reported insider transactions by 10X Fund, L.P., 10X Capital Management, LLC, and Director James C. Czirr on 10/22/2025. The filing lists two open‑market sales: 20,000 shares at $4.93 and 30,000 shares at $4.94.

Following these sales, the reporting persons show 5,872,207 shares beneficially owned. The form indicates direct ownership for the reported balance and includes standard footnotes stating that certain parties may be deemed to have indirect beneficial ownership, with ownership disclaimed except to the extent of pecuniary interest.

Galectin Therapeutics (GALT) ha riportato operazioni di insider by 10X Fund, L.P., 10X Capital Management, LLC e dal Direttore James C. Czirr il 22/10/2025. Il deposito elenca due vendite sul mercato aperto: 20.000 azioni a 4,93 $ e 30.000 azioni a 4,94 $.

Dopo queste vendite, le persone segnalanti mostrano 5.872.207 azioni possedute direttamente. Il modulo indica la proprietà diretta per il saldo riportato e include note a piè di pagina standard che indicano che alcune parti possono essere considerate come aventi una proprietà benefica indiretta, con la proprietà rifiutata se non nell'ambito dell'interesse pecuniario.

Galectin Therapeutics (GALT) informó transacciones de insiders por 10X Fund, L.P., 10X Capital Management, LLC, y el Director James C. Czirr el 22/10/2025. La presentación registra dos ventas en el mercado abierto: 20.000 acciones a $4.93 y 30.000 acciones a $4.94.

Después de estas ventas, las personas informantes muestran 5.872.207 acciones beneficiosas. El formulario indica propiedad directa del saldo informado e incluye notas al pie estándares que señalan que ciertas partes pueden ser consideradas como propietarias beneficiosas indirectas, con la propiedad renunciada excepto en la medida del interés pecuniario.

Galectin Therapeutics (GALT) 는 10X Fund, L.P., 10X Capital Management, LLC 및 이사 James C. Czirr의 내부자 거래를 2025-10-22에 보고했습니다. 신고서는 두 건의 공개시장 매도를 열거합니다: 4.93달러에 20,000주4.94달러에 30,000주.

이 매도 이후, 보고 당사자들은 5,872,207주를 유익하게 보유하고 있음을 보여줍니다. 양식은 보고된 잔액에 대해 직접 소유권을 나타내고, 특정 당사자들이 간접적 유익 소유권을 갖는 것으로 간주될 수 있음을 명시하는 표준 각주를 포함하며, pecuniary interest의 범위에서만 소유권을 포기합니다.

Galectin Therapeutics (GALT) a rapporté des transactions d'initiés par 10X Fund, L.P., 10X Capital Management, LLC, et le directeur James C. Czirr le 22/10/2025. Le dossier récapitule deux ventes sur le marché libre : 20 000 actions à 4,93 $ et 30 000 actions à 4,94 $.

Suite à ces ventes, les personnes déclarantes détiennent 5 872 207 actions détenues bénéficiaires. Le formulaire indique une propriété directe du solde déclaré et comprend des notes de bas de page standard indiquant que certaines parties peuvent être considérées comme détenant une propriété bénéficiaire indirecte, la propriété étant abandonnée sauf dans la mesure de l'intérêt pécuniaire.

Galectin Therapeutics (GALT) berichtete Insider-Transaktionen durch 10X Fund, L.P., 10X Capital Management, LLC, und Director James C. Czirr am 10/22/2025. Die Einreichung listet zwei Open-Market-Verkäufe auf: 20.000 Aktien zu 4,93 $ und 30.000 Aktien zu 4,94 $.

Nach diesen Verkäufen zeigen die meldenden Personen 5.872.207 Aktien im Beneficial Ownership. Das Formular weist direkte Eigentumsverhältnisse für den gemeldeten Saldo aus und enthält Standardfußnoten, die besagen, dass bestimmte Parteien als indirektes wirtschaftliches Eigentum gelten können, wobei Eigentum außerhalb des Umfangs des finanziellen Interesses abgelehnt wird.

Galectin Therapeutics (GALT) أبلغت عن معاملات داخلية من قبل 10X Fund, L.P.، و10X Capital Management, LLC، والمدير James C. Czirr في 22/10/2025. يسرد الملف تسجيلين للبيع في السوق المفتوح: 20,000 سهم بسعر 4.93 دولار و30,000 سهم بسعر 4.94 دولار.

بعد هذه المبيعات، يظهر الأشخاص المبلغون عنهم 5,872,207 سهمًا مملوكًا ملكية مستفيدة. يشير النموذج إلى الملكية المباشرة للرَصيد المُبلغ عنه ويتضمن ملاحظات هامشية قياسية تشير إلى أن بعض الأطراف قد يعتبرون مالكين مستفيدين بشكل غير مباشر، مع رفض الملكية إلا بقدر المصالح المالية.

Positive
  • None.
Negative
  • None.

Galectin Therapeutics (GALT) ha riportato operazioni di insider by 10X Fund, L.P., 10X Capital Management, LLC e dal Direttore James C. Czirr il 22/10/2025. Il deposito elenca due vendite sul mercato aperto: 20.000 azioni a 4,93 $ e 30.000 azioni a 4,94 $.

Dopo queste vendite, le persone segnalanti mostrano 5.872.207 azioni possedute direttamente. Il modulo indica la proprietà diretta per il saldo riportato e include note a piè di pagina standard che indicano che alcune parti possono essere considerate come aventi una proprietà benefica indiretta, con la proprietà rifiutata se non nell'ambito dell'interesse pecuniario.

Galectin Therapeutics (GALT) informó transacciones de insiders por 10X Fund, L.P., 10X Capital Management, LLC, y el Director James C. Czirr el 22/10/2025. La presentación registra dos ventas en el mercado abierto: 20.000 acciones a $4.93 y 30.000 acciones a $4.94.

Después de estas ventas, las personas informantes muestran 5.872.207 acciones beneficiosas. El formulario indica propiedad directa del saldo informado e incluye notas al pie estándares que señalan que ciertas partes pueden ser consideradas como propietarias beneficiosas indirectas, con la propiedad renunciada excepto en la medida del interés pecuniario.

Galectin Therapeutics (GALT) 는 10X Fund, L.P., 10X Capital Management, LLC 및 이사 James C. Czirr의 내부자 거래를 2025-10-22에 보고했습니다. 신고서는 두 건의 공개시장 매도를 열거합니다: 4.93달러에 20,000주4.94달러에 30,000주.

이 매도 이후, 보고 당사자들은 5,872,207주를 유익하게 보유하고 있음을 보여줍니다. 양식은 보고된 잔액에 대해 직접 소유권을 나타내고, 특정 당사자들이 간접적 유익 소유권을 갖는 것으로 간주될 수 있음을 명시하는 표준 각주를 포함하며, pecuniary interest의 범위에서만 소유권을 포기합니다.

Galectin Therapeutics (GALT) a rapporté des transactions d'initiés par 10X Fund, L.P., 10X Capital Management, LLC, et le directeur James C. Czirr le 22/10/2025. Le dossier récapitule deux ventes sur le marché libre : 20 000 actions à 4,93 $ et 30 000 actions à 4,94 $.

Suite à ces ventes, les personnes déclarantes détiennent 5 872 207 actions détenues bénéficiaires. Le formulaire indique une propriété directe du solde déclaré et comprend des notes de bas de page standard indiquant que certaines parties peuvent être considérées comme détenant une propriété bénéficiaire indirecte, la propriété étant abandonnée sauf dans la mesure de l'intérêt pécuniaire.

Galectin Therapeutics (GALT) berichtete Insider-Transaktionen durch 10X Fund, L.P., 10X Capital Management, LLC, und Director James C. Czirr am 10/22/2025. Die Einreichung listet zwei Open-Market-Verkäufe auf: 20.000 Aktien zu 4,93 $ und 30.000 Aktien zu 4,94 $.

Nach diesen Verkäufen zeigen die meldenden Personen 5.872.207 Aktien im Beneficial Ownership. Das Formular weist direkte Eigentumsverhältnisse für den gemeldeten Saldo aus und enthält Standardfußnoten, die besagen, dass bestimmte Parteien als indirektes wirtschaftliches Eigentum gelten können, wobei Eigentum außerhalb des Umfangs des finanziellen Interesses abgelehnt wird.

Galectin Therapeutics (GALT) أبلغت عن معاملات داخلية من قبل 10X Fund, L.P.، و10X Capital Management, LLC، والمدير James C. Czirr في 22/10/2025. يسرد الملف تسجيلين للبيع في السوق المفتوح: 20,000 سهم بسعر 4.93 دولار و30,000 سهم بسعر 4.94 دولار.

بعد هذه المبيعات، يظهر الأشخاص المبلغون عنهم 5,872,207 سهمًا مملوكًا ملكية مستفيدة. يشير النموذج إلى الملكية المباشرة للرَصيد المُبلغ عنه ويتضمن ملاحظات هامشية قياسية تشير إلى أن بعض الأطراف قد يعتبرون مالكين مستفيدين بشكل غير مباشر، مع رفض الملكية إلا بقدر المصالح المالية.

Galectin Therapeutics (GALT) 报告了由 10X Fund, L.P.、10X Capital Management, LLC 和董事 James C. Czirr 于 2025-10-22 的内幕交易。该文件列出两笔公开市场卖出:20,000 股,价格 4.93 美元30,000 股,价格 4.94 美元

在这些交易之后,申报人显示拥有 5,872,207 股的受益所有权。该表格指示对报告余额的直接所有权,并包含标准脚注,表明某些方可能被视为间接受益所有权,所有权在涉及金钱利益的范围内才被放弃。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
10X Fund, L.P.

(Last) (First) (Middle)
545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)
ATLANTA, GA 30324

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/22/2025 S 20,000 D $4.93 5,902,207 D(1)
Common Stock 10/22/2025 S 30,000 D $4.94 5,872,207 D(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
10X Fund, L.P.

(Last) (First) (Middle)
545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)
ATLANTA, GA 30324

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
10X Capital Management, LLC

(Last) (First) (Middle)
545 DUTCH VALLEY ROAD, N.E., SUITE A

(Street)
ATLANTA, GA 30324

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
CZIRR JAMES C

(Last) (First) (Middle)
4908 SOUTH ASHTON COURT

(Street)
SPOKANE WA 99223

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
/s/ James C. Czirr, as Managing Member of the General Partner for 10X Fund, LP 10/23/2025
/s/ James C. Czirr, as Managing Member of 10X Capital Management, LLC 10/23/2025
/s/ James C. Czirr, Individually 10/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were disclosed for GALT?

Two sales on 10/22/2025: 20,000 shares at $4.93 and 30,000 shares at $4.94.

How many GALT shares are beneficially owned after the transactions?

The filing reports 5,872,207 shares beneficially owned following the transactions.

Who are the reporting persons on this GALT Form 4?

10X Fund, L.P., 10X Capital Management, LLC, and James C. Czirr (Director).

What was the transaction date for the GALT insider sales?

The sales occurred on 10/22/2025.

Were the reported holdings listed as directly owned?

Yes, the post‑transaction holdings are shown as Direct (D), with a footnote regarding potential indirect beneficial ownership and related disclaimers.

Did the filing indicate use of a Rule 10b5-1 trading plan?

The form includes the 10b5‑1 checkbox language, but the excerpt does not indicate that the box was checked.
Galectin Therapeutics Inc

NASDAQ:GALT

GALT Rankings

GALT Latest News

GALT Latest SEC Filings

GALT Stock Data

330.78M
45.05M
30.08%
16.46%
12.47%
Biotechnology
Pharmaceutical Preparations
Link
United States
NORCROSS